Regeneron Pharmaceuticals’ combo therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet AMD.
Shares of Threshold Pharmaceuticals plunged more than 58 percent in pre-market trading after the company announced it was terminating about one-fourth of its workforce following the failure of its Phase II cancer treatment.
Alnylam Pharmaceuticals recently presented 10 posters and oral presentations showing the progress of its GalNAc platform and its clinical translation at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Montreal. Included in the presentations was a bit of a bomb – in its Phase I/II study of ALN-AAT to treat AAT deficiency-associated liver disease (alpha-1 liver disease), three patients showed asymptomatic, transient increased liver enzymes. As a result, it has halted.
After a strategic review of its operations and pipeline, Waltham, Massachusetts-based ImmunoGen announced that it will cut 17 percent of its staff, or 65 jobs.
Just a day after Hanmi Pharmaceutical announced a deal with Genentech, Boehringer Ingelheim terminated a license deal because of patient deaths.
Alcobra Ltd.’s market value more than halved a day after the company said the U.S. Food and Drug Administration had placed a hold on its lead experimental drug.
The Zika virus can infect and alter cells in the human nervous system that are crucial for formation of bones and cartilage in the skull, a study found.
Horizon Pharma said it would pay pharmacy benefit manager Express Scripts Holding $65 million to settle litigation related to after-market rebates for three of its medicines.
Amgen Inc. said it would buy a stake in Arrowhead Pharmaceuticals Inc. and collaborate with the company to develop gene-silencing therapies for heart disease.
Create My Faculty Document Write my college paper, please… We acquire numerous similar messages on the daily basis. Today, it is an extremely tough job to be always an effective scholar since instructors assign plenty of undertaking to complete, while learners basically have no time to handle all jobs by the due date.
MediGene and bluebird bio struck a collaborative deal to develop T cell receptor (TCR) immunotherapies against four targets that could be worth more than $1 billion.
Genentech, a member of the Roche Group, licensed HM95573 from Seoul, South Korea-based Hanmi Pharmaceutical Co. for a deal that could hit $910 million.
Every once in a while it’s refreshing for a healthcare digital strategist or innovation officer to take a close look at how marketing technology is being used outside of pharma.
The world’s largest insulin maker, Novo Nordisk, is cutting 1,000 jobs as a part of a plan to reduce costs as it faces a challenging environment in 2017, especially in the large U.S. market.
Swiss biotech group Actelion Ltd. will investigate an all-oral combination therapy for patients with relapsing multiple sclerosis (RMS), calling it the first study of this approach for treating the neurological disorder.
Medtronic Plc won U.S. approval for an “artificial pancreas” that is the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes, freeing them from continually monitoring insulin levels throughout each day.
Two simple tests that can be done in a doctor’s office may be able to rule in or out a painful hip condition that is usually hard to diagnose without magnetic resonance imaging (MRI), according to a small study.
U.S. Senators Richard Blumenthal, Charles Grassley and Amy Klobuchar asked the Justice Department to investigate whether Mylan NV may have misclassified its EpiPen in order to pay lower rebates to the states.
Boehringer Ingelheim and ViraTherapeutics will jointly develop a next-generation oncolytic virus therapy platform and investigate ViraTherapeutics’ lead candidate.
Biogen will test Anavex Life Sciences’ lead drug candidate, ANAVEX 2-73, in an oligodendrocyte precursor cell (OPC) differentiation assay.